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Abstract
The aetiology of depressive disorder remains unknown, although genetic susceptibility and exposure to
neurotoxins are currently being discussed as possible contributors to this disorder. In normal circum-
stances, the brain is protected against bloodborne toxic inﬂuences by the blood–brain barrier, which
includes the molecular eﬄux pump P-glycoprotein (P-gp) in the vessel wall of brain capillaries. We
hypothesized that P-gp function in the blood–brain barrier is changed in patients with major depression.
Positron emission tomography was used to measure brain uptake of [11C]verapamil, which is normally
expelled from the brain by P-gp. Cerebral volume of distribution (VT) of [
11C]verapamil was used as a
measure of P-gp function. Both region-of-interest (ROI) analysis and voxel analysis using statistical
parametric mapping (SPM2) were performed to assess regional brain P-gp function. We found that
patients with a major depressive episode, using antidepressants, compared to healthy controls showed a
signiﬁcant decrease of [11C]verapamil uptake in diﬀerent areas throughout the brain, in particular in
frontal and temporal regions. The decreased [11C]verapamil uptake correlates with an increased function
of the P-gp protein and may be related to chronic use of psychotropic drugs. Our results may explain why
treatment-resistant depression can develop.
Received 29 August 2008 ; Reviewed 22 October 2008 ; Revised 8 December 2008 ; Accepted 11 December 2008 ;
First published online 19 February 2009
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Introduction
A large body of evidence gathered during the past
decades indicates that brain monoaminergic systems
play a key role in the pathogenesis of aﬀective dis-
orders. However, not all symptoms of depression
can be related to dysfunctions in monoaminergic sys-
tems. For instance, it is now known that stressful
events paving the way to aﬀective disorders, lead to
changes in neuroplasticity, impair neurogenesis and
may lead to a neuroinﬂammatory response in the
brain (Trentani et al. 2003). As such, it has been sug-
gested that a dysfunction of the blood–brain barrier
(BBB) and blood–cerebrospinal ﬂuid (CSF) barrier
may contribute to the pathophysiology of major de-
pressive disorder (MDD). Hampel and colleagues re-
ported that serum/CSF ratios of several inﬂammatory
proteins (used as an indirect measure of BBB function)
were altered in depression (Hampel et al. 1995, 1997).
Several endogenous substances, such as cortisol, are
found in the brain parenchyma in high concentrations
in subjects with a MDD. In normal circumstances the
BBB limits the access of cortisol to the brain (Karssen
et al. 2001).
The BBB is formed by the brain capillary non-
fenestrated polarized endothelial cells that have
high-resistanct tight junctions. Besides low passive
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permeability, the brain is protected from potentially
harmful endogenous and exogenous substances by
eﬄux transporter proteins, located in the brain capil-
lary wall.
P-glycoprotein (P-gp), a product of the MDR1 gene
in humans and the MDR-1a and MDR-1b genes in
mice, is a major drug eﬄux transporter, involved in
the eﬄux of a wide variety of lipophilic drugs and
endogenous substances (Schinkel et al. 1994). At-
tenuation of P-gp function, for example through use
of pharmacological inhibitors, results in substantial
changes in the pharmacokinetics and pharmaco-
dynamics of various substrates (Cordon-Cardo et al.
1990 ; Loscher & Potschka, 2005 ; Schinkel et al. 1996).
Nuclear medicine imaging techniques such as
positron emission tomography (PET) have been eval-
uated as non-invasive techniques for the evaluation of
the BBB, allowing study of the P-gp pump (Elsinga
et al. 2004). Using several experimental designs, the
applicability of [11C]verapamil as a PET tracer has been
extensively studied (Elsinga et al. 1996 ; Hendrikse
et al. 1998, 1999) and has been found to be a suitable
methodology for the in-vivo assessment of P-gp func-
tionality in humans (Sasongko et al. 2005) and allows
the quantiﬁcation of BBB P-gp function in neuro-
degenerative diseases (Elsinga et al. 2004 ; Hendrikse
et al. 1998, 1999 ; Kortekaas et al. 2005).
The protective role of P-gp may be negatively
inﬂuenced in neurodegenerative diseases. Animal
models of neuroinﬂammation have demonstrated that
P-gp is down-regulated by pro-inﬂammatory cyto-
kines (Bauer et al. 2005 ; Fernandez et al. 2004 ; McRae
et al. 2003).
In a recent PET study using [11C]verapamil it was
found that the function of BBB P-gp was diminished in
later stages of Parkinson’s disease, whereas de-novo
patients with Parkinson’s showed a regional up-
regulation of P-gp in frontal regions (Bartels et al.
2008a). In another [11C]verapamil PET study in patients
with schizophrenia it was shown that P-gp function
was locally increased (O. L. de Klerk et al. unpublished
observations). The authors stated that P-gp induction
may be critically involved in the development of
drug resistance in schizophrenia. P-gp function is
possibly under the inﬂuence of genetic polymor-
phisms (Hoﬀmeyer et al. 2000).
To date, no detailed evidence is available showing
dysfunction of the BBB through P-glycoprotein modu-
lation in MDD. It is not known whether P-gp function
or expression is altered during a depressive episode.
In this exploratory study we hypothesized that P-gp
function would be altered in limbic areas (hippocam-
pus, amygdala) as well in frontotemporal areas
(including anterior cingulate cortex) since these areas
are known to play a role in depression (Drevets, 1999;
Mayberg, 2002). We further hypothesized that this al-
tered functional activity of P-gp could be connected to
a genetic polymorphism of the MDR1 gene. To assess
these hypothesized changes in P-gp function, PET
brain imaging with [11C]verapamil as radiotracer was
performed in depressed patients and healthy controls.
The distribution volume of [11C]verapamil was used as
a measure of total P-gp function.
Methods
Subjects
Fourteen patients suﬀering from depression were re-
cruited and participated in the study. All underwent
a Mini International Neuropsychiatric Interview
(M.I.N.I. plus 5.0.0., Dutch version, 2000) for DSM-IV
and fulﬁlled the criteria for a major depressive episode
(Sheehan et al. 1998). Inclusion criteria for subjects
with a major depressive episode were (1) age 40–80 yr ;
(2) fulﬁlment of DSM-IV criteria for major depressive
episode; and (3) capacity to give informed consent.
The age range 40–80 yr was chosen, because we ex-
pected to ﬁnd larger diﬀerences at a later age in par-
ticular, since P-gp function declines with ageing
(Bartels et al. 2008b). Moreover, the control group was
also used in another study. Exclusion criteria were (1)
use of known P-gp modulating agents (cardiovascular
drugs, antimalarial drugs, cyclosporine A, phenothia-
zines, hormones (e.g. tamoxifen), certain antibiotics
such as cefoperazone, ceftriaxone, erythromycin)
(Matheny et al. 2001) ; (2) any somatic disease of kid-
ney, liver, heart or brain ; (3) history of traumatic brain
damage; (4) electroconvulsive treatment in the past
3 months ; (5) abnormalities at clinical (including
neurological) and laboratory examination; (6) preg-
nancy. Antidepressant medication was allowed. This
research was approved by the Ethics Committee of
the University Medical Centre Groningen, and all
subjects gave written informed consent according to
the Declaration of Helsinki. All patients had a mini-
mum score of at least 19 on the 17-item Hamilton
Depression Rating Scale (HAMD) at the time of the
PET study (Hamilton, 1960). All patients had a phys-
ical examination and laboratory evaluation. All were
in good physical health and none had meaningful
laboratory abnormalities.
The healthy controls as well as their ﬁrst-degree
relatives were required to have no history of any psy-
chiatric disease. The other inclusion and exclusion
criteria for healthy controls were similar to the
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patients. Before the scan, blood was drawn from the
venous cannula for genotyping. Three commonMDR1
single nucleotide polymorphisms (SNPs) were de-
tected using a PCR analysis.
Radiochemistry
Racemic [11C]verapamil was produced as previously
described (Wegman et al. 2002). The injected radioac-
tivity of [11C]verapamil was comparable for the control
group and subjects with a major depressive episode
(see Results section). Speciﬁc activity for all subjects
was at least 16 GBq/mmol. Following radiotracer in-
jection, subjects underwent a dynamic PET acquisition
protocol as described previously (Kortekaas et al.
2005).
PET procedure
All scans were performed with the use of an ECAT
EXACT HR+ positron camera (Siemens/CTI, USA).
After the radiotracer injection of [11C]verapamil serial
dynamic PET scanning was done at escalating time-
frames and serial arterial blood sampling for [11C]ver-
apamil took place during the scan in order to deﬁne
the input function. The samples of all subjects were
collected with an automated sampling system, to-
gether with six manually drawn samples per subject.
These samples (collected at 10-min intervals) were
further processed to measure the radioactivity in
plasma and blood. In this way the contribution of the
injected activity to the PET signal could be calculated.
No metabolite analysis was performed. Images were
reconstructed in brain mode using an iterative re-
construction (ordered subsets – expectation maxi-
mization) with four iterations and 16 subsets and a
Gaussian ﬁlter of 4 mm. The scans were performed in
3D mode.
Data analysis
The PET data were analysed with both a voxel-wise
group analysis using statistical parametric mapping
(SPM2, The Mathworks Inc., USA) and a ROI (regions
of interest)-based approach. Results from both meth-
ods were used and compared.
First, all images were stereotaxically normalized to
MNI space using SPM2 and a [11C]verapamil template
image that could be used from earlier studies of our
group (Bartels et al. 2008a ; Kortekaas et al. 2005). The
resulting images were analysed with SPM2 as de-
scribed below. For the ROI analysis the following
ROIs, based on the literature as cited above, were
selected for analysis : prefrontal cortex, anterior
cingulate cortex, temporal lobes, amygdala and hip-
pocampus. Therefore, predeﬁned ROIs from the
Anatomical Automated Labeling package (Tzourio-
Mazoyer et al. 2002) were used to select the appropriate
voxels and calculate the corresponding time–activity
curves using in-house developed software. In ad-
dition, a whole brain ROI was manually drawn using
Clinical Applications Programming Package software
(CAPP; CTI/Siemens PET Systems, USA).
A graphical analysis according to Logan for
quantiﬁcation of the dynamic PET data was done with
plasma data as input. The Logan plot was started at
5 min. With this method the distribution volume (VT)
was estimated. Because the slope (i.e. VT eﬀect) ob-
tained in the graphical approach may be biased in the
presence of noisy data (Abi-Dargham et al. 2000), we
veriﬁed the VT in a kinetic analysis (i.e. single tissue
compartment model). The inﬂux rate constant (K1) and
eﬄux k2 were derived from this model and on all
parameters (i.e. VT, K1 and k2) the group means (pa-
tient group vs. control group) were compared with
each other, using parametric tests. Analysis of covari-
ance was performed in order to ﬁnd relevant (clinical)
predictors (age, length of present episode, number of
previous episodes, severity of symptoms) of VT or K1.
To exclude a possible confounding eﬀect of subjects
without a strict DSM-IV diagnosis of MDD, a sub-
analysis was also done for the group with MDD only
(n=10).
Data were then analysed with SPM2. To adjust for
diﬀerences in individual neuroanatomy and to im-
prove the signal-to-noise ratio, a 12-mm full-width at
half-maximum Gaussian smoothing ﬁlter was applied
to all images. We ﬁrst compared the groups by look-
ing at absolute diﬀerences in VT, using t test and
ANCOVA with cofactors (MDR1 allelic variation,
age, length of present episode, number of previous
trials, severity of symptoms, injected activity of
[11C]verapamil). Clusters of o8 voxels at a threshold
of pFDR<0.05 (false discovery rate) were considered to
be signiﬁcant. Coordinates were transformed into
Talairach space (Talairach & Tournoux, 1988) using the
mni2tal-transformation (http://www.mrc-cbu.cam.
ac.uk/Imaging/).
Results
The mean injected [11C]verapamil dose was not dif-
ferent for the two groups (control group: mean=
317 MBq, S.D.=119; group with depression: mean=
279 MBq, S.D.=179; t test : t=x0.344; d.f.=24;
p=0.734). Table 1 shows the demographic character-
istics and medication use of the patient group. Twelve
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patients had a previous depressive episode, three
patients had a bipolar type I disorder, the current
episode being depressive. Three subjects had a de-
pressive episode with psychotic features. One patient
was excluded from the analysis because the VT was
considered an outlier, since the diﬀerence to the group
mean was 4.6 times the standard deviation of the
group for unknown reasons. The patient group [6 fe-
male/7 males, mean (¡S.D.) age 54.1¡7.6 yr] was
compared to a sex-matched comparison group (6 fe-
male and 7 male subjects ; mean age 56.3¡14.3 yr).
Patients had a mean score of 25.8 (¡4.8) on the 17-item
HAMD (range 19–37). Nine patients were currently
depressed for >12 wk. Interestingly, seven of this
group could be considered to be treatment resistant,
using the criteria of Dunner (2006). Comorbid dis-
orders included post-traumatic stress disorder (PTSD)
(n=1) and panic disorder (n=1). All subjects used an
antidepressant or a mood stabilizer at the time of
scanning.
We determined three common MDR1 SNPs
(x129 T>C (exon 1), 2677 G>T/A (exon 21) and
3435 C>T (exon 26)) in our patient group. For the SNP
3435 on exon 26 the allele frequencies in the patient
group were CC 23%, CT 38% and TT 39%. The allele
frequencies of SNP 3435 in our subjects were not dif-
ferent from the frequency in the population (Tan et al.
2004).
The mean brain time–activity curves (after correc-
tion for weight and injected dose) for the whole brain
of patient and control groups were compared and the
area under the curve (AUC) was calculated. No dif-
ferences in the AUC were found. Both curves over-
lapped (data not shown). The VT values of the ROI
(whole brain) were calculated with both the Logan
analysis and the ‘single tissue compartment model’, in
order to verify that the VT eﬀect measured by the
Logan method was concordant with another method.
Pearson’s correlation coeﬃcient (r) was very good,
1.000 (p=0.000). The Logan curve gave an excellent ﬁt
Table 1. Characteristics of subjects with major depressive episode
Subject
no.
Treatment
setting Gender
Age
(yr)
Age of
onset
(yr)
Length of
PE (wk) DSM-IV HAMD Medication
1 PC M 47 22 20 BP-I, D, P 22 Valproic acid 2000 mg/d (level 79 mg/l) ;
venlafaxine 225 mg/d, risperidone 2 mg/d
2 O F 72 67 12 MDD 20 Mirtazapine 30 mg/d, temazepam
20 mg 1 dd 1, cetirizine 10 mg/d
3 PC F 71 45 104 MDD 25 Imipramine 100 mg/d; lactulose 30 ml/d;
esomeprazole 20 mg/d; quetiapine 200 mg/d
4 DT F 51 27 26 BP-I, D 22 Lithium carbonate 900 mg/d
(level 0.88 mg/l) ; diclofenac 150 mg/d
5 PC F 52 33 26 MDD, P 37 Tranylcypromine 60 mg/d;
olanzapine 15 mg/d
6 PC M 60 60 8 MDD, P 26 Citalopram 20 mg/d
7 PC M 56 51 52 MDD, PTSD 31 Lithium carbonate 1000 mg/d
(level 0.90 mg/l) ; nortriptyline 100 mg/d
8 PC M 55 23 26 MDD, PD 25 Nortriptyline 100 mg/d
9 PC F 56 31 104 MDD 27 Tolderodine 4 mg/d; temazepam
20 mg/d; cisordinol 2 mg/d;
mirtazapine 30 mg/d
10 O M 41 39 6 MDD 24 Citalopram 40 mg/d; mirtazapine
30 mg/d; oxazepam 50 mg/d
11 PC F 52 38 12 BP-I 29 Valproic acid 1500 mg/d; temazepam
20 mg/d; asacol ; thyrax 75 mg/d
12 PC M 46 46 20 MDD 24 Venlafaxine 150 mg/d
13 PC M 52 44 6 MDD 30 Venlafaxine 150 mg/d
14 O F 57 56 12 MDD 19 Mirtazapine 30 mg/d; citalopram 20 mg/d
BP-I, bipolar disorder type I ; D (current phase) depressive ; DT, day treatment ; HAMD, Hamilton Depression Rating Scale ;
MDD, major depressive disorder, O, Outpatient ; P, psychotic features ; PC, psychiatric clinic ; PD, panic disorder ; PE, present
episode ; PTSD, post-traumatic stress disorder.
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in all cases. The VT in ROI whole brain in the group of
patients (n=13) with depression was lower at a nearly
signiﬁcant level (Z=x2.008, p=0.055). K1 (whole
brain ROI) showed no signiﬁcant diﬀerence between
the groups (values given are mean¡S.D.) [0.48¡0.15
(controls) vs. 0.41¡0.10 (patients), p=0.15]. Neither
did the k2 values [0.71¡0.10 (controls) vs. 0.75¡0.15
(patients), p=0.46]. In the ANCOVA none of the co-
factors (age, length of present episode, number of
previous episodes, severity of symptoms) showed a
signiﬁcant eﬀect on the results.
Both groups were compared with a Student’s t test
for the selected ROIs (prefrontal cortex, anterior cingu-
late cortex, temporal lobes, hippocampus, amygdala).
Here we found a signiﬁcantly lower VT in the patient
group for the prefrontal cortex [0.64¡0.20 (controls)
vs. 0.44¡0.15 (patients), p=0.009], the temporal lobes
[0.66¡0.21 (controls) vs. 0.44¡0.19 (patients), p=0.01],
the anterior cingulate cortex [0.53¡0.20 (controls) vs.
0.34¡0.18 (patients), p=0.016], and for amygdala
[0.72¡0.30 (controls) vs. 0.49¡0.24 (patients), p=
0.045] but not for hippocampus [0.55¡0.32 (controls)
vs. 0.41¡0.13 (patients), p=0.146]. VT diﬀerences in
prefrontal cortex and temporal lobes were signiﬁcant
after Bonferroni correction for multiple tests. K1 and k2
showed no diﬀerences between the groups for any of
the ROIs. The mean¡S.D. of VT for each group are
shown for each ROI in Fig. 1.
A pixelrpixel t test (without scaling) comparing
both groups (13 vs. 13) in SPM2, showed several clus-
ters, mainly located in temporal and frontal regions, in
which the tracer uptake (VT) was lower in the patient
group, pFDR=0.028 (see Table 2). The largest cluster
measured 52 cm3, including predominantly temporal
lobes, reaching from the precentral gyrus to cerebel-
lum and to the parietal lobes. The other large cluster
(36 cm3) included the prefrontal cortex (see Fig. 2). The
clusters that reached statistical signiﬁcance overlapped
to a great extent with the areas found in the ROI
analysis. Length of present episode (in weeks), HAMD
scores, number of previous episodes, allelic variation
of MDR-1 polymorphisms 3435C>T and 2677G>T,
diagnosis and administered verapamil activity as
covariates in ANCOVA had no signiﬁcant eﬀect as
confounder on the results.
A subanalysis of the 10 patients with MDDwas also
performed. The subset was compared to a matched
control group both at ROI level and in a voxel-wise
analysis in SPM2. The results in the voxel-based ap-
proach indicated a somewhat stronger decrease in
Table 2. Characteristics of signiﬁcant clusters in SPM2
Cluster
size (cm3) pFDR-corr
T value
(max) MNI coordinates Location
52.8 0.028 3.66 x38,x2,x10 Left temporal lobe, grey matter
0.028 3.62 x12,x6, 8 Left thalamus, ventral anterior nucleus
0.028 3.40 28, 12,x24 Right temporal lobe, superior temporal gyrus
35.6 0.028 3.64 44, 26, 22 Right frontal lobe middle frontal gyrus
3.37 x20, 46, 22 Left frontal lobe, superior frontal gyrus
8.0 0.028 3.37 x42,x52,x18 Left cerebellum
1.5 0.028 2.83 x4,x62, 4 Left occipital lobe, lingual gyrus
4.3 0.028 2.81 x6,x2,6 48 Left frontal lobe, paracentral lobule
1.20
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0.00
0.80
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Fig. 1. t test comparison of the two groups at selected regions
of interest (ROI). Distribution volume (VT) (#, mean ; ,
standard deviation) is shown in regions relevant for
depression. ACC, anterior cingulate cortex ; PFC, prefrontal
cortex ; C, control group; D, patient group with a depressive
episode (n=13) ; MD, subgroup of patients with a major
depressive disorder (n=10). Both patient groups showed a
signiﬁcant decrease in VT in all regions except the
hippocampus (* p<0.05, ** p<0.05 after Bonferroni
correction).
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VT compared to the control group. A large cluster
(240 cm3, pFDR=0.016, tmax=4.83) was found, com-
prising mainly temporal lobes and frontal cortex (data
not shown). The VT in ROI whole brain was also sig-
niﬁcantly lower than in the matched control group
[0.75¡0.25 (controls) vs. 0.55¡0.08 (MDD), p=0.030].
The results for selected ROIs are shown in Fig. 1.
Finally, we compared the subgroup of patients with
a treatment-resistant depressive episode (n=7) to a
matched control group. This comparison gave com-
parable results in both approaches as the analysis of
the whole group (n=13) did, yielding a signiﬁcant
decrease in VT both at ROI level and at voxel level
in the group with a treatment-resistant depressive
episode (data not shown).
Discussion
This study shows a signiﬁcantly lowered [11C]vera-
pamil uptake (VT) in prefrontal cortex and temporal
lobes in patients with a major depressive episode. The
results of diﬀerent methods of analysis were all in ac-
cordance with each other.
In functional imaging studies the prefrontal cortex
and temporal lobes have often been associated with
MDD (Brody et al. 2001 ; Drevets, 2000). To our know-
ledge this is the ﬁrst study showing involvement of
P-gp in medicated patients with MDD.
Seven of the 13 patients studied were considered to
be treatment resistant, most patients were admitted
to a psychiatric hospital, indicating either a severe
depressive episode or a chronic course of the illness.
Although clinical parameters indicating treatment re-
sistance or chronicity were not signiﬁcant cofactors in
ANCOVA, a signiﬁcant decrease in VT (in temporal
and frontal areas) was found in a subset of patients
with a treatment-resistant depressive disorder (com-
pared to a matched control group).
Treatment resistance in depression may in fact be
associated with increased P-gp function. Increased P-
gp function may cause low uptake of antidepressants.
Similar to treatment-resistant epilepsy where in-
creased expression of P-gp is associated with resist-
ance to anti-epileptics and poor prognosis (Loscher &
Potschka, 2002 ; Sisodiya et al. 2001), treatment resist-
ance may also have inﬂuenced our results.
Regional diﬀerences in VT may reﬂect localized re-
gions of higher P-gp function, which may be under the
inﬂuence of a functional polymorphism of MDR1. The
SNP C3435T has been associated with altered P-gp
function, albeit in an intestinal cell line (Hoﬀmeyer
et al. 2000), which does not necessarily reﬂect the P-gp
expression in brain cells. However, the impact of
genetic variations in the MDR1 gene on the course of
MDD or the response to antidepressants is considered
to be moderate or absent, and results are conﬂicting
(Eichelbaum et al. 2004 ; Laika et al. 2006; Mihaljevic-
Peles et al. 2007 ; Qian et al. 2006 ; Woodahl & Ho, 2004).
The frequencies of the determined polymorphism in
our study group did not diﬀer from the frequencies
seen in the general population (Tan et al. 2004;
Woodahl & Ho, 2004).
(a)
(b)
3
2
1
0
Fig. 2. T-map showing a diminished distribution volume of [11C]verapamil in 13 patients with a depressive episode compared to
the healthy control group (n=13). The clusters that reached statistical signiﬁcance in a voxel-wise t test (pFDR<0.05) (in SPM2)
are shown. (a) Signiﬁcant projections on a glass brain. (b) MRI overlay : a large cluster located in frontal cortex, left and right
temporal lobes, and subcortical nuclei is shown.
900 O. L. de Klerk et al.
Our results may also be explained by a neuroin-
ﬂammatory process. There is increasing evidence for
the role of cytokines in the pathogenesis of depression.
Inﬂammation results in the release of pro-inﬂam-
matory cytokines, acting as a neuromodulator and
accounting for most of the symptoms in depression
(Raison et al. 2006 ; Schiepers et al. 2005). Experimental
animal models of inﬂammation show that inﬂam-
mation can inﬂuence P-gp expression and activity in
diﬀerent ways (Fernandez et al. 2004 ; McRae et al.
2003 ; Monville et al. 2002). Although a decrease in
function and expression of P-gp seems to be the case
in acute inﬂammatory models, the study by Tan and
colleagues shows that P-gp function was increased
after the acute inﬂammatory phase (Tan et al. 2002).
The course of a depressive episode may be similar
in such a way that in the chronic phase P-gp is up-
regulated. Post- mortem studies are warranted to
conﬁrm these hypotheses. It is desirable that further
(neuroimaging) studies are conducted to shed light on
the neuroinﬂammatory events in MDD.
Regional diﬀerences in VT could be explained by an
increase in atrophy in cortical brain areas in major
depression. However, the most consistent ﬁndings in
studies using structural MRI is reduction in hippo-
campal volume (Videbech & Ravnkilde, 2004) and
basal ganglia, whereas atrophy in frontal regions has
been found less consistently. The most robust re-
duction in VT, in our study was seen in the temporal
lobes. The fact that no diﬀerences in VT were found in
the hippocampus at ROI level may be due to spill-in of
radioactivity of the adjacent choroid plexus, since is
has been reported that there is a high accumulation of
radioactivity in the choroid plexus (Langer et al. 2007).
A possible limitation of the present study is the fact
that patients were treated with antidepressant medi-
cation. The increase in P-gp function in our study
could be caused by the use of medication. Drugs or
substances that are known to enhance P-gp expression
were all excluded from our study (see Table 1). Many
of the antidepressant and antipsychotic drugs used are
substrates for P-gp, but their eﬀect on P-gp activity is
probably not clinically relevant (El Ela et al. 2004 ; Peer
et al. 2004 ; Weber et al. 2005; Weiss et al. 2003a).
Several antidepressants and anticonvulsants are
known to inhibit the P-gp pump in a concentration-
dependent manner in porcine brain cells (Peer et al.
2004 ; Weber et al. 2005 ; Weiss et al. 2003a, b). In in-vitro
studies of antipsychotics inhibition of P-gp was only
seen in concentrations above therapeutically relevant
plasma levels, thus suggesting that the inhibitory ef-
fect of antipsychotics may not play a role in clinical
practice (El Ela et al. 2004 ; Weber et al. 2005). Recently,
it was found that venlafaxine (used by three patients)
can induce P-gp in human Caco-2 cells (Ehret et al.
2007). Nevertheless, the implication of chronic use
of antidepressant and/or antipsychotic drugs is not
known. It cannot be excluded that antidepressant
and/or antipsychotic agents given for a sustained
period lead to an up-regulation of the P-gp pump. To
rule out this possibility, future studies in medication-
naive patients are needed.
In addition to a possible eﬀect on P-gp function,
medication may also have inﬂuenced the metabolism
of [11C]verapamil. It is known that anticonvulsants in-
ﬂuence [11C]verapamil metabolism, probably through
induction of cytochrome P450 (Abrahim et al. 2008).
Two of our patients were on valproic acid. However,
leaving these two patients out of the analysis made no
diﬀerence to the results. Medication may also have
inﬂuenced the free fraction of [11C]verapamil, leading
to a lower VT eﬀect in the patient group. The inﬂux
parameter (K1) suggested no diﬀerence between the
two groups, due to a large variance. The fact that only
certain areas (i.e. temporal lobes and prefrontal cortex)
showed a signiﬁcant decrease in VT cannot be ex-
plained in this way.
In the present study no analysis of metabolites was
performed. Although this can be seen as another
limitation of the study, we assume that the total con-
tribution of metabolites, that contribute to the PET
signal, but have no aﬃnity for the P-gp pump, is small.
Only the N-demethylated fraction (so-called polar
fraction) has no aﬃnity for P-gp (Lubberink et al. 2007 ;
Pauli-Magnus et al. 2000 ; Sasongko et al. 2005). As
Lubberink et al. (2007) have shown the ‘one tissue
compartment’ model gives an excellent ﬁt of the data,
irrespective of metabolite input. Their data indicate
that the contribution of the polar fraction to the
brain signal is small. However, it cannot be excluded
that chronic use of antipsychotic and antidepressant
agents may have inﬂuenced the metabolism of
[11C]verapamil, thereby reducing brain uptake of the
radiotracer in patients. However, the fact that a de-
crease in VT is only seen in speciﬁc areas can probably
not be attributed to the metabolites of [11C]verapamil.
In summary, in our PET study using [11C]verapamil
as a tracer, we have found evidence for an increased
function of P-gp in patients with a major depressive
episode under long-term treatment conditions, which
for the ﬁrst time may provide an explanation for
treatment resistance in patients suﬀering from MDD.
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